Altimmune completes dosing in the Phase 2 MOMENTUM trialAltimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
First patients treated with ECLIPSIUM hernia repair systemThe first patients have been treated with Tissium's ECLIPSIUM adhesive hernia repair system and have undergone laparoscopic ventral...
Viking begins VENTURE trial of dual glp-1/gip receptor agonist VK2735 for obesityViking Therapeutics has initiated a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like...
Allurion launches Coach Iris generative AI-powered weight loss coachAllurion Technologies has launched Coach Iris, a new generative AI-powered health coach designed to enhance outcomes within the Allurion...
Survodutide GLP-1 receptor dual agonist to be assessed in three global Phase III studies for obesityBoehringer Ingelheim will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for...
Skooterama launches a bariatric scooters Skooterama, a provider of mobility solutions, has expanded its product line with the launch of Bariatric Scooters. According to the...
Aardvark Therapeutics gains Rare Pediatric Disease Designation for Prader-Willi Syndrome The FDA has granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare...